drugset / Trial / NCT07523048

Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder

NCT07523048

Phase 2 Recruiting 30 enrolled Roger McIntyre Axsome Therapeutics, Inc. · collab
NaSingle-groupOpen-labelOther

Summary

This study will look at how a new medication (dextromethorphan and bupropion taken together in one pill) affects the brain in people with depression. All participants will take the medication for two weeks and have brain scans done. Since people with depression often feel reduced enjoyment in day-to-day activities, our goal is to learn if this treatment can change brain activities in ways that could help improve mood and enjoyment in life.

Timeline

Start
2025-11-21
Primary completion
2026-07
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 105 mg
Subject Dextromethorphan Unknown 45 mg